India, March 12 -- Gilead Sciences, Inc. (GILD) Wednesday said it presented encouraging long-term data from ALLIANCE study.
ALLIANCE is an ongoing Phase 3 study to evaluate Biktarvy versus dolutegravir plus emtricitabine/tenofovir disoproxil fumarate F/TDF, DTG+F/TDF, in adults with HIV-1/HBV co-infection initiating treatment.
New data from the study showed that Biktarvy maintained 95.4% of HIV-1 and 86.6% of HBV virologic suppression in participants following a switch to Biktarvy after 96 weeks of treatment with DTG+ F/TDF.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
These data were presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2025).
Additionally, the company s...